New treatment for cardiac arrest using VBI-1
Development of VBI-1 as a novel treatment protocol for outpatient cardiac arrest
This study is testing a new treatment called VBI-1 for people who have had a cardiac arrest, aiming to improve blood flow and oxygen to the heart and brain during resuscitation to help them survive and reduce brain injury.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Vivacelle Bio, INC. NIH-funded |
| Lab location | 1 site (Fort Wayne, UNITED STATES) |
| Project ID | NIH-10921818 on NIH RePORTER |
What this research studies
This research investigates a novel treatment protocol called VBI-1 for patients experiencing cardiac arrest, a critical condition that can lead to severe complications or death. The approach focuses on improving blood flow and oxygen delivery to the heart and brain during resuscitation, aiming to enhance survival rates and reduce brain injury. VBI-1 is a specially formulated solution that helps restore effective blood circulation and minimizes damage caused by the lack of oxygen. The study will involve testing this treatment in a controlled setting to evaluate its effectiveness compared to standard resuscitation fluids.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals who have suffered a cardiac arrest and require immediate resuscitation interventions.
Not a fit: Patients who are not experiencing cardiac arrest or those with pre-existing severe health conditions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly improve survival rates and recovery outcomes for patients who experience cardiac arrest.
How similar studies have performed: Previous studies have shown promising results with similar approaches in animal models, indicating potential for success in human applications.
Where this research is happening
Fort Wayne, UNITED STATES
- Vivacelle Bio, INC. — Fort Wayne, United States (Active)
Researchers
- Principal investigator: Simpkins, Cuthbert Ormond — Vivacelle Bio, INC.
- Study coordinator: Simpkins, Cuthbert Ormond
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.